Aquestive Therapeutics In... (AQST)
3.08
0.05 (1.65%)
At close: Feb 20, 2025, 3:59 PM
3.08
0.04%
After-hours: Feb 20, 2025, 05:44 PM EST
undefined% (undefined)
| Bid | 3.08 |
| Market Cap | 280.83M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -0.45 |
| PE Ratio (ttm) | -6.84 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 3.13 |
| Volume | 1,383,841 |
| Avg. Volume (20D) | 1,717,601 |
| Open | 3.04 |
| Previous Close | 3.03 |
| Day's Range | 2.95 - 3.21 |
| 52-Week Range | 2.24 - 6.23 |
| Beta | undefined |
About AQST
Aquestive Therapeutics, Inc., a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral ...
Sector Healthcare
IPO Date Jul 25, 2018
Employees 135
Stock Exchange NASDAQ
Ticker Symbol AQST
Website https://www.aquestive.com
Analyst Forecast
According to 8 analyst ratings, the average rating for AQST stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 192.21% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
Aquestive Therapeutics Inc. is scheduled to release its earnings on Mar 5, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
2 months ago
+5.2%
Aquestive Therapeutics shares are trading higher a...
Unlock content with
Pro Subscription
2 months ago
+6.94%
Aquestive Therapeutics shares are trading higher after Cantor Fitzgerald initiated coverage on the stock with an Overweight rating and announced a price target of $17.
